An Open-label, 3-Part, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of MK7009
Latest Information Update: 11 May 2022
At a glance
- Drugs Vaniprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 23 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Jun 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
- 14 Jun 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.